Pyrukynd (Mitapivat Sulfate) Patent Expiration, LOE Window & CMS Spending

Pyrukynd (Mitapivat Sulfate) by Agios: FDA Orange Book core substance LOE 2038-11-21 (last listed 2041-07-31), 0 AB generics, $12.7M 2024 CMS Part D & Medicaid spend, and $32,610 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAgios
FDA Application & PathwayN216196 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-11-21
Last Listed Patent or Exclusivity Date2041-07-31
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$12.7M
2024 Medicare Part D Spend$6.0M
2024 Medicaid Spend$6.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($32,610 intro WAC)